(Author Opinion) Vertical Integration in Pharmacy Software Systems — A Risk to Pharmacy Stability
- Todd Eury
- 7 minutes ago
- 6 min read
Across centuries, storytellers warned of forces so vast and mesmerizing that entire ships, cities, and civilizations were pulled under without realizing the danger until it was too late. The Leviathan symbolized overwhelming power rising from the depths, impossible to escape once engaged. The Sirens lured sailors with promises of harmony, only to steer them toward destruction on hidden rocks. In modern pharmacy, massive technology takeovers can feel strikingly similar—presented as seamless integration, efficiency, and scale, yet carrying the risk of market dominance so expansive that independence, competition, and operational autonomy quietly erode beneath the surface. What appears to be progress can, without guardrails, become something far more consuming and risk the further closing of pharmacies across the nation.
Vertical Integration in Healthcare vs. Vertical Integration in Pharmacy Tech & Switching Services — A Growing Threat to Pharmacy Stability with consolidation of pharmacy software systems.
Vertical integration, the consolidation of multiple stages of a value chain under a single corporate umbrella, has been promoted as a mechanism for efficiency, coordination, and cost containment in healthcare. We all know the headlines right now, right?
Senators Elizabeth Warren and Josh Hawley introduced the "Break Up Big Medicine Act" in February 2026, aiming to prohibit companies from simultaneously owning health insurers/PBMs and medical providers. (from Becker’s Hospital Review January 22nd, 2026)
In theory, aligning insurance coverage, pharmacy benefit management, provider services, and dispensing functions should reduce friction and create seamless patient experiences. In practice, however, vertical integration has raised escalating concerns about market concentration, pricing opacity, patient steering, and innovation stagnation.
PBM Reform is in the news almost everyday, we all know the truth now about the 3-biggest PBM’s impact on pharmacy desserts, pharmacy services, independent pharmacies closing, and the limited access to medications in many cases. These concerns are no longer confined to payers and PBMs. They are now emerging in the pharmacy software and technology sector, where consolidation among pharmacy management system vendors is reshaping the operational backbone of independent pharmacies nationwide.
Does one company possess too much control?
Within healthcare delivery, vertical integration typically means insurers owning PBMs, specialty pharmacies, retail chains, and sometimes physician groups. Corporations such as CVS Health, UnitedHealth Group, and Cigna span insurance underwriting, drug price negotiation, and medication dispensing. While this model is often framed as “streamlined care,” regulators and lawmakers increasingly question whether such integration restricts competition and narrows patient choice.
I spent 10 years in pharmacy software business development, marketing and sales. I saw what happened when one pharmacy software system takes over another. It’s not all ‘Smooth Sailing’ – it can be – and was many times disastrous to pharmacy operators.
A parallel consolidation is now occurring in pharmacy technology infrastructure. Pharmacy management systems (PMS), billing engines, data analytics tools, and POS platforms form the digital nervous system of pharmacy operations. As companies like RedSail Technologies expand through acquisitions such as PrimeRx, interoperability and scale efficiencies may indeed improve. Integration across workflow automation, logistics platforms, and reporting tools can strengthen operational alignment in a tight reimbursement environment.
But just like in the 'gobble up' of healthcare insurance companies, PBMS, and other entities, consolidation reduces vendor diversity and increases dependency risk. To much control at the hands of V.C. investors with the lure of commoditizing the brains of a pharmacy operations, could one company control the software systems of 50% or more of the 60,000+ pharmacies in the U.S.?
When a dominant software vendor controls integration via APIs, software interface permissions, data exchange standards, and the product roadmap, competitive pressure diminishes. Independent pharmacies may face bundled pricing models, altered support tiers, and strategic shifts that prioritize ecosystem expansion over niche operational needs. Switching costs rise as platforms become more interconnected, and data portability concerns intensify. Over time, this can produce a technology monoculture in which innovation cycles slow and pricing leverage erodes.
Don't forget about Powerline, the claims switch
Powerline is a switch solution owned by RedSail Technologies, which also owns major pharmacy management systems like PrimeRx, PioneerRx and QS/1. I haven’t been able to find clear, current data on Powerline’s market share, but it's mutliple parts of the pie controlled by the V.C. backed pharmacy software provider. It's important not to forget that the relationship between pharmacy management systems and switches isn’t strictly one-to-one.
Over the past five years, there has been no clear, publicly available dataset detailing pharmacy claims switch pricing or precise market share, as this information is typically proprietary and embedded within broader contracts involving PBMs, PSAOs, and pharmacy software vendors. However, transaction volume serves as a strong proxy for industry activity.
For example, Surescripts reported growth from approximately 17.5 billion transactions in 2020 to over 30 billion by 2025, reflecting a significant expansion driven by increased e-prescribing, real-time benefit checks, and automation in prior authorizations. Despite this growth, upstream control of prescription claims remains highly concentrated, with the majority processed by the three largest PBMs, which indirectly influences how switch networks operate and compete.
At the same time, the role of switches has evolved beyond simple claims routing into more complex platforms that support data exchange, workflow automation, and patient engagement tools. While legacy players like Change Healthcare and RelayHealth still dominate, newer entrants and integrated solutions—such as Surescripts’ expanded capabilities and RedSail’s Powerline—are contributing to a more competitive landscape.
Economically, traditional per-transaction fees (historically estimated in the range of a few cents per claim) are becoming less transparent as pricing shifts toward bundled service models and data-driven revenue streams. Overall, the industry is seeing rising volume, increasing functional complexity, and continued opacity in pricing and market dynamics.
PBMs who own pharmacies and pharmacy software companies who own switches?
RedSail Technologies’ acquisition of RxMile highlights a strategic move to strengthen its ecosystem of solutions for independent pharmacies by adding a purpose-built delivery management platform. The article explains how RxMile enables pharmacies to streamline and optimize prescription delivery through features like real-time tracking, route optimization, virtual signatures, and HIPAA-compliant workflows, helping improve efficiency, reduce errors, and enhance patient experience. What does this mean for one company controlling so many pieces of the PMS ecosystem?
There's huge opportunities for the remaining indepdnetnly owned pharmacy software tech platforms to anticipate the needs of the future of pharmacy services. This is where Blue Ocean Strategy provides an instructive contrast.
Developed by W. Chan Kim and Renée Mauborgne, Blue Ocean Strategy argues that lasting success comes not from competing in saturated “red oceans,” but from creating uncontested market space through value innovation — the simultaneous pursuit of differentiation and low cost. In healthcare and pharmacy technology, vertical integration often reflects red ocean dynamics: consolidation to capture margin, defend market share, and intensify control within crowded industries. The focus becomes competitive dominance rather than expanding value for patients or providers.
True value innovation in pharmacy would look different. It would involve open, interoperable systems that lower operational costs while enhancing clinical capabilities. It would reward transparency, foster API openness, and empower independent operators rather than locking them into proprietary ecosystems. Instead of controlling distribution channels to extract margin, innovators would redesign workflows to eliminate friction and elevate patient outcomes at lower total system cost.
When vertical integration substitutes scale for innovation, the industry risks mistaking consolidation for progress. Operational efficiency can improve in the short term, but without competitive tension and open architecture, long-term dynamism suffers. Independent pharmacies — already navigating reimbursement compression, DIR fee volatility, and staffing shortages — may become increasingly vulnerable to both payer-controlled ecosystems and software vendor concentration.
The comparison between healthcare delivery integration and pharmacy software consolidation reveals a shared structural risk: market power centralizes, bargaining leverage declines, and transparency weakens.
While integration can streamline processes, it can also entrench dependency. The sustainability of pharmacy operations nationwide depends not merely on scale, but on competitive balance and value innovation. If the profession is to avoid becoming trapped in increasingly “bloody” red oceans, stakeholders must prioritize open systems, diversified vendor ecosystems, and regulatory guardrails that protect competition — ensuring that stability, affordability, and patient-centered care remain the true north of pharmacy’s future.
What could happen in the pharmacy software space with one company devouring the others, based on the history of ‘vertical like integrations'?
Leviathan Sea-Monster of the pharmacy software wars
Yep, the Leviathan Sea-Monster of the pharmacy software wars is thrashing in the red-oceans of market grab. That's the goal. Market grab, growth, expansion and targeting the next pharmacy software aquisition. The sea-Sirens are luring the pharmacy owner and operator 'sailors' with promises of harmony, effecincy, and advanced technolgies, and they'll control everything. So, if I specualted, who decides if RedSail's Investors - Leonard Green & Partners (LGP) and Francisco Partners don't sell it all to CVS Health & Aetna's backers Vanguard and BlackRock?
This doesn’t feel right to me. - Todd Eury
